Lumos Pharma, Inc.
LUMO
$-0.06
Change (1 day)
$4.55
Year High
$1.37
Year Low
Categories
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
P/E ratio for Lumos Pharma, Inc. (LUMO)
P/E ratio as of 2023: -0.76
According to Lumos Pharma, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.76. At the end of 2022 the company had a P/E ratio of -0.97.
P/E ratio history for Lumos Pharma, Inc. from 2008 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.76 |
| 2022 | -0.97 |
| 2021 | -1.90 |
| 2020 | -42.74 |
| 2019 | -0.01 |
| 2018 | -0.12 |
| 2017 | -0.39 |
| 2016 | -0.39 |
| 2015 | -2.86 |
| 2014 | 1.20 |
| 2013 | -1.98 |
| 2012 | -1.24 |
| 2011 | -0.26 |
| 2010 | -0.70 |
| 2009 | -1.20 |
| 2008 | -1.23 |